Uncoupling of p21 induction and MyoD activation results in the failure of irreversible cell cycle arrest in doxorubicin-treated myocytes

Pier Lorenzo Puri, Stefania Medaglia, Letizia Cimino, Carlo Maselli, Antonia Germani, Elisabetta De Marzio, Massimo Levrero, Clara Balsano

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Doxorubicin (Dox, Adriamicin), a potent broad spectrum anthracycline anticancer drug, selectively inhibits muscle specific gene expression in cardiac cells in vivo and prevents terminal differentiation of skeletal muscle cells in vitro. By inducing the expression of the helix-loop-helix (HLH) transcriptional inhibitor Id2, Dox represses the myogenic function of the MyoD family of muscle regulatory factors (MRFs). In many cell types, terminal differentiation is coupled to an irreversible exit from the cell cycle and MyoD plays a critical role in the permanent cell cycle arrest of differentiating myocytes by upregulating the cyclin dependent kinase inhibitor (cdki) p21. Here, we correlate Dox effects on cell cycle with changes of E2F/DP complexes and activity in differentiating C2C12 myocytes. In Dox-treated quiescent myoblasts, which fail to differentiate into myotubes under permissive culture conditions, serum re-stimulation induces cyclin/cdk re association on the E2F/DP complexes and this correlates with an evident increase in E2F/DP driven transcription and re-entry of myoblasts into the cell cycle. Despite Dox ability to activate the DNA-damage dependent p53/p21 pathway, when induced in the absence of MyoD or other MRFs, p21 fails to maintain the postmitotic state in Dox-treated myocytes induced to differentiate. Thus, uncoupling p21 induction and MyoD activity results in a serum-reversible cell cycle arrest, indicating that MRF specific activation of cdki(s) is required for permanent cell cycle arrest in differentiating muscle cells.

Original languageEnglish
Pages (from-to)27-36
Number of pages10
JournalJournal of Cellular Biochemistry
Volume66
Issue number1
DOIs
Publication statusPublished - Jul 1 1997

Fingerprint

Cell Cycle Checkpoints
Doxorubicin
Muscle Cells
Chemical activation
Cells
Muscle
Muscles
Cell Cycle
Myoblasts
Cyclin-Dependent Kinase Inhibitor p21
Cyclins
Cyclin-Dependent Kinases
Anthracyclines
Skeletal Muscle Fibers
Serum
DNA Damage
Cell Differentiation
Skeletal Muscle
Reentry
Transcription

Keywords

  • Cell cycle
  • Doxorubicin/adriamicin
  • E2F
  • MyoD
  • p21

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology

Cite this

Uncoupling of p21 induction and MyoD activation results in the failure of irreversible cell cycle arrest in doxorubicin-treated myocytes. / Puri, Pier Lorenzo; Medaglia, Stefania; Cimino, Letizia; Maselli, Carlo; Germani, Antonia; De Marzio, Elisabetta; Levrero, Massimo; Balsano, Clara.

In: Journal of Cellular Biochemistry, Vol. 66, No. 1, 01.07.1997, p. 27-36.

Research output: Contribution to journalArticle

Puri, Pier Lorenzo ; Medaglia, Stefania ; Cimino, Letizia ; Maselli, Carlo ; Germani, Antonia ; De Marzio, Elisabetta ; Levrero, Massimo ; Balsano, Clara. / Uncoupling of p21 induction and MyoD activation results in the failure of irreversible cell cycle arrest in doxorubicin-treated myocytes. In: Journal of Cellular Biochemistry. 1997 ; Vol. 66, No. 1. pp. 27-36.
@article{f26097d5c649418ea8812c13c85f240e,
title = "Uncoupling of p21 induction and MyoD activation results in the failure of irreversible cell cycle arrest in doxorubicin-treated myocytes",
abstract = "Doxorubicin (Dox, Adriamicin), a potent broad spectrum anthracycline anticancer drug, selectively inhibits muscle specific gene expression in cardiac cells in vivo and prevents terminal differentiation of skeletal muscle cells in vitro. By inducing the expression of the helix-loop-helix (HLH) transcriptional inhibitor Id2, Dox represses the myogenic function of the MyoD family of muscle regulatory factors (MRFs). In many cell types, terminal differentiation is coupled to an irreversible exit from the cell cycle and MyoD plays a critical role in the permanent cell cycle arrest of differentiating myocytes by upregulating the cyclin dependent kinase inhibitor (cdki) p21. Here, we correlate Dox effects on cell cycle with changes of E2F/DP complexes and activity in differentiating C2C12 myocytes. In Dox-treated quiescent myoblasts, which fail to differentiate into myotubes under permissive culture conditions, serum re-stimulation induces cyclin/cdk re association on the E2F/DP complexes and this correlates with an evident increase in E2F/DP driven transcription and re-entry of myoblasts into the cell cycle. Despite Dox ability to activate the DNA-damage dependent p53/p21 pathway, when induced in the absence of MyoD or other MRFs, p21 fails to maintain the postmitotic state in Dox-treated myocytes induced to differentiate. Thus, uncoupling p21 induction and MyoD activity results in a serum-reversible cell cycle arrest, indicating that MRF specific activation of cdki(s) is required for permanent cell cycle arrest in differentiating muscle cells.",
keywords = "Cell cycle, Doxorubicin/adriamicin, E2F, MyoD, p21",
author = "Puri, {Pier Lorenzo} and Stefania Medaglia and Letizia Cimino and Carlo Maselli and Antonia Germani and {De Marzio}, Elisabetta and Massimo Levrero and Clara Balsano",
year = "1997",
month = "7",
day = "1",
doi = "10.1002/(SICI)1097-4644(19970701)66:1<27::AID-JCB4>3.0.CO;2-#",
language = "English",
volume = "66",
pages = "27--36",
journal = "Journal of Cellular Biochemistry",
issn = "0730-2312",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Uncoupling of p21 induction and MyoD activation results in the failure of irreversible cell cycle arrest in doxorubicin-treated myocytes

AU - Puri, Pier Lorenzo

AU - Medaglia, Stefania

AU - Cimino, Letizia

AU - Maselli, Carlo

AU - Germani, Antonia

AU - De Marzio, Elisabetta

AU - Levrero, Massimo

AU - Balsano, Clara

PY - 1997/7/1

Y1 - 1997/7/1

N2 - Doxorubicin (Dox, Adriamicin), a potent broad spectrum anthracycline anticancer drug, selectively inhibits muscle specific gene expression in cardiac cells in vivo and prevents terminal differentiation of skeletal muscle cells in vitro. By inducing the expression of the helix-loop-helix (HLH) transcriptional inhibitor Id2, Dox represses the myogenic function of the MyoD family of muscle regulatory factors (MRFs). In many cell types, terminal differentiation is coupled to an irreversible exit from the cell cycle and MyoD plays a critical role in the permanent cell cycle arrest of differentiating myocytes by upregulating the cyclin dependent kinase inhibitor (cdki) p21. Here, we correlate Dox effects on cell cycle with changes of E2F/DP complexes and activity in differentiating C2C12 myocytes. In Dox-treated quiescent myoblasts, which fail to differentiate into myotubes under permissive culture conditions, serum re-stimulation induces cyclin/cdk re association on the E2F/DP complexes and this correlates with an evident increase in E2F/DP driven transcription and re-entry of myoblasts into the cell cycle. Despite Dox ability to activate the DNA-damage dependent p53/p21 pathway, when induced in the absence of MyoD or other MRFs, p21 fails to maintain the postmitotic state in Dox-treated myocytes induced to differentiate. Thus, uncoupling p21 induction and MyoD activity results in a serum-reversible cell cycle arrest, indicating that MRF specific activation of cdki(s) is required for permanent cell cycle arrest in differentiating muscle cells.

AB - Doxorubicin (Dox, Adriamicin), a potent broad spectrum anthracycline anticancer drug, selectively inhibits muscle specific gene expression in cardiac cells in vivo and prevents terminal differentiation of skeletal muscle cells in vitro. By inducing the expression of the helix-loop-helix (HLH) transcriptional inhibitor Id2, Dox represses the myogenic function of the MyoD family of muscle regulatory factors (MRFs). In many cell types, terminal differentiation is coupled to an irreversible exit from the cell cycle and MyoD plays a critical role in the permanent cell cycle arrest of differentiating myocytes by upregulating the cyclin dependent kinase inhibitor (cdki) p21. Here, we correlate Dox effects on cell cycle with changes of E2F/DP complexes and activity in differentiating C2C12 myocytes. In Dox-treated quiescent myoblasts, which fail to differentiate into myotubes under permissive culture conditions, serum re-stimulation induces cyclin/cdk re association on the E2F/DP complexes and this correlates with an evident increase in E2F/DP driven transcription and re-entry of myoblasts into the cell cycle. Despite Dox ability to activate the DNA-damage dependent p53/p21 pathway, when induced in the absence of MyoD or other MRFs, p21 fails to maintain the postmitotic state in Dox-treated myocytes induced to differentiate. Thus, uncoupling p21 induction and MyoD activity results in a serum-reversible cell cycle arrest, indicating that MRF specific activation of cdki(s) is required for permanent cell cycle arrest in differentiating muscle cells.

KW - Cell cycle

KW - Doxorubicin/adriamicin

KW - E2F

KW - MyoD

KW - p21

UR - http://www.scopus.com/inward/record.url?scp=0030741255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030741255&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-4644(19970701)66:1<27::AID-JCB4>3.0.CO;2-#

DO - 10.1002/(SICI)1097-4644(19970701)66:1<27::AID-JCB4>3.0.CO;2-#

M3 - Article

C2 - 9215525

AN - SCOPUS:0030741255

VL - 66

SP - 27

EP - 36

JO - Journal of Cellular Biochemistry

JF - Journal of Cellular Biochemistry

SN - 0730-2312

IS - 1

ER -